TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04042727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: Six vials of Dexmedetomidine hydrochloride 100mcg/ml (2ml per vial) will be added to a 250mL bag of normal saline by the investigational pharmacy to prepare for infusion by patient's bedside nurse. Infusion rate will be 1mcg/kg/hr.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.5% sodium chloride (NaCl). The investigational pharmacy will prepare the normal saline placebo 250mL bag for infusion by patient's bedside nurse. Infusion will be 1mcg/kg/hr.
Study: NCT02939326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB-001 injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB-001 injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB-001 injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB-001 injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB-001 injection
Study: NCT00445965

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131 monoclonal antibody 3F8

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 131I-3F8
Description: Patients will receive 10mCi intrathecal 131I-3F8 per week. Patients will be pre-medicated with dexamethasone to prevent possible meningeal inflammatory reaction, Liothyronine and SSKI to prevent thyroid accumulation, and acetaminophen and diphenhydramine in anticipation of possible allergic reaction and fever.
Study: NCT02586896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengths-based Case Management (SBCM)
Description: The six case management sessions for the proposed trial are based on those described in manuals developed by Dr. Rapp for two clinical trials, one supported by National Institute on Drug Abuse (NIDA) and another by the Centers for Disease Control (CDC). Each session is guided by specific objectives that promote linkage with and retention in substance abuse treatment, particularly pharmacotherapy for opioid dependence in a specialty or primary care setting. Objectives from the earlier trials will be adapted to fit the specific context of this trial, linking with and staying in treatment following an emergency department visit. Initiation of the relationship between client and case manager begins immediately following random assignment and termination takes place when either (1) six sessions have occurred; (2) ninety days have elapsed; or (3) clients discontinue involvement.
Study: NCT02939326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB-001 injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB-001 injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Study: NCT03384394

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-flow nasal cannula oxygen
Description: high-flow nasal cannula oxygen

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional oxygen therapy
Description: oxygen by a standard nasal cannula or nonrebreather mask
Study: NCT03795324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Redlove Apple intervention
Description: The bioactive compounds present in this product are anthocyanins (50mg per 80g of product).It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized redlove apple.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green Apple intervention
Description: It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized green apple.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aronia drink intervention
Description: The bioactive compounds present in this extract are anthocyanins (50mg per 1L of water).It was a 6 weeks nutritional intervention. Volunteers will drink 1L per day of an aronia drink
Study: NCT00098774

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/sq m IV infusion (max rate of 400 mg/hr) on Days 3, 10, 17, \& 24 of Cycle 1 nad Days 3 \& 10 of Cycle 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 2 g/sq m IV infusion over 2 hours q 12 hrs x 8 doses Days 1-4 of Cycle 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 5 mg/kg IV infusion over 12 hrs q 12 hrs x 8 doses Days 1-4 of Cycle 6
Study: NCT01440231

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered by subcutaneous injection, once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept 5 mg administered by subcutaneous injection, once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept 25 mg administered by subcutaneous injection, once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept 75 mg administered by subcutaneous injection, once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept 115 mg administered by subcutaneous injection, once weekly
Study: NCT03812614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAM ACT
Description: Patient and Support Person (dyad) will receive a Diabetes Complications Risk Assessment profile and introduction session, Support Person-focused information/skills training through 4-6 extended DSME sessions, case management contacts with CHW throughout the duration of the 6-month intervention, and guidance on how to prepare for and participate in healthcare appointments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: I-DSMES
Description: Patient only will receive a Diabetes Complications Risk Assessment profile and introduction session, 4-6 group DSME sessions, case management contacts with CHW throughout the duration of the 6-month intervention, and guidance on how to prepare for and participate in healthcare appointments.
Study: NCT00642317

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire about tobacco and alcohol use, acculturation, and other related topics.
Study: NCT04132674

Intervention type: DRUG
Group type: OTHER
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide
Description: Taking one oral tablet of B/F/TAF once-daily for 72 weeks
Study: NCT02229526

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low dose fish oil
Description: Four 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 2.7 g n-3 fatty acids per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low dose olive oil
Description: Four 1 g capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose fish oil
Description: Nine 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 6.1 g n-3 fatty acids per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High dose olive oil
Description: Nine 1g gelatine capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.
Study: NCT03951116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-437
Description: FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.
Study: NCT05825885

Intervention type: DRUG
Intervention: E2
Description: micronized E2 at a daily dose of 4-6mg,

Intervention type: DRUG
Intervention: E2
Description: micronized E2 at a daily dose of 4-6mg,

Intervention type: DRUG
Intervention: E2
Description: micronized E2 at a daily dose of 4-6mg,
Study: NCT03137329

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise program
Description: Physical therapy for aerobic and resistance training exercises

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise program
Description: Physical therapy for aerobic and resistance training exercises

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nutrition
Description: Nutrition supplementation via HMR for lifestyle arm only

Intervention type: PROCEDURE
Group type: OTHER
Intervention: WLS
Description: Weight loss surgery as planned
Study: NCT02195895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Weekly oral alendronate 70 mg for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Daily oral 1000 mg Calcium

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Daily oral 1000 IU
Study: NCT04421430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distraction cards
Description: The distraction cards contain various hidden pictures and patterns which are visible only when looked at carefully. During a procedure, the child is expected to focus on the cards and answer the questions asked about what they see in them. Just before the venipuncture, the researcher showed the distraction cards participants the distraction cards and asked them to check them and then asked them questions about what they saw on the cards and kept asking questions until the end of the venipuncture. The distraction cards intervention and venipuncture were terminated at the same time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The virtual reality participants put on the virtual reality glasses and headsets about two minutes before the venipuncture and watched the 3D Dinosaur Animation movie throughout the procedure. The virtual reality intervention and venipuncture were terminated at the same time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buzzy
Description: Buzzy® applies high frequency vibration and concentrated cold at injection site for procedural pain management and distraction before the shot in children and adults. Buzzy® was placed on the injection site (antecubital fossa) of the Buzzy® participants, and cold application and vibration was turned on 60 seconds before the procedure. After the 60 seconds, the nurse moved Buzzy® about 3 cm above the injection site and applied a tourniquet and performed the procedure. Buzzy® was on throughout the procedure. The Buzzy® intervention and venipuncture were terminated at the same time.
Study: NCT01343732

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep TMS
Description: deep transcranial magnetic stimulation
Study: NCT02586896

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening, Assessment, and Referral (SAR)
Description: The research assistant will provide these participants with an information sheet listing treatment (including both specialty treatment centers and primary care clinics that provide buprenorphine) and self-help resources in their community. The referral sheet includes names, addresses, and phone numbers of local addiction treatment agencies. Because the emergency department does not currently screen or refer systematically, the SAR condition represents a level of care significantly higher than treatment as usual. Participants will also receive an informational pamphlet about drug use and its consequences, addiction, and treatment.
Study: NCT00089349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given PO
Study: NCT03448185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Description: Subjects will be randomized to the exercise groups will undergo 1 year aerobic exercise training comprised of high intensity exercise sessions 2-3 days per week. Sessions will be supervised remotely via heart rate monitors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High intensity exercise
Description: Subjects will be randomized to the exercise groups will undergo 1 year aerobic exercise training comprised of high intensity exercise sessions 2-3 days per week. Sessions will be supervised remotely via heart rate monitors.
Study: NCT01343732

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep TMS
Description: deep transcranial magnetic stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep TMS
Description: deep transcranial magnetic stimulation
Study: NCT03813992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MED2005
Description: Topical Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MED2005
Description: Topical Product
Study: NCT04324983

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Additional blood sample of about 30 ml that will be drawn for biomarker analyses (2 EDTA = ethylenediaminetetraacetic acid and 1 Cell-search-tubes).The drawn blood for CTC-Analysis and biomarker identification will be promptly processed ac-cording to the established standards at the Institute for Tumor Biology (see below).~The histological analysis of the resected tissue during salvage surgery is carried out according to clinical routine (conventional haematoxylin and eosin stained and PSMA-Immunohistochemistry). Additionally, tissue samples will undergo molecularpathological analysis if this does not affect routine pathological examination.
Study: NCT03040180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy with bleomycin
Description: Systemic injection, once only treatment
Study: NCT03813992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MED2005
Description: Topical Product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MED2005
Description: Topical Product
Study: NCT01377870

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravenous injection of mesenchymal stem cells
Description: 15 patients with relapsing remitting multiple sclerosis underwent intravenous injection of mesenchymal stem cell
Study: NCT04245722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Conditioning agent
Study: NCT01377870

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: injection of cell free media
Description: Patients who are in control group underwent media injection but after 6 months they will be transplanted by stem cell.
Study: NCT01807377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: 200 mg tablet administered twice per day for 14 days
Study: NCT03040180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoVE
Description: Electroporation using an endoscopic electroporation device
Study: NCT02554916

Intervention type: BEHAVIORAL
Intervention: Dual-Belt Exercise
Description: The dual-belted exercise treadmill can control the speeds of the right and left legs individually. When asymmetric, the dual-belt treadmill imposes mechanical and sensory perturbations independently to each leg such that the central nervous system (CNS) must solve and adapt to the challenge to maintain walking.
Study: NCT01807377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 2mg administered as single doses on Days 0 and 11

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered twice per day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 2mg administered as single doses on Days 0 and 11
Study: NCT02207959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine Hemisulphate salt
Description: The stomach will be sprayed with 1-10 ml of 0.01% proflavine using a standard endoscopic spray-catheter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: White-light examination
Description: standard white light examination

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging with High Resolution Microendoscope
Description: HRME will be inserted through the biopsy channel of the endoscope, gently placed against the mucosa, and images of suspicious areas will be obtained.
Study: NCT00898456

Intervention type: GENETIC
Intervention: gene expression analysis

Intervention type: GENETIC
Intervention: molecular genetic technique

Intervention type: GENETIC
Intervention: polymorphism analysis

Intervention type: GENETIC
Intervention: protein expression analysis
Study: NCT02554916

Intervention type: BEHAVIORAL
Intervention: Treadmill Exercise
Description: The treadmill exercise will maintain the speed of the right and left leg together while walking.

Intervention type: OTHER
Intervention: Usual Care
Description: This group will not be assigned to a treadmill but is as a non-exercising control group.

Intervention type: DEVICE
Intervention: Dual-Belt Treadmill

Intervention type: DEVICE
Intervention: Dual-Belt Treadmill
Study: NCT00898456

Intervention type: OTHER
Intervention: diagnostic laboratory biomarker analysis
Study: NCT03561818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-based pulmonary rehabilitation
Description: The patients who undergo two days pulmonary rehabilitation under supervision in our clinic and three days a week at home during two months will taken as hospital group. The exercises include breathing exercises, treadmill (15sc), cycle training (15sc), arm ergometer training (15sc), peripheral muscle training and stretching exercises with free weights.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation
Description: The patients who follow a home-based pulmonary rehabilitation program for two months comprising breathing exercises, training in chest hygiene techniques, peripheral muscle strengthening training and self-walking for 5 days in a week for two months. An exercise follow-up form will give to the patients to record their daily exercises. A similar form will fill by physiotherapist once a week during phone call.
Study: NCT03037983

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: rTMS is a non-invasive procedure, in which the administration of a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention will be administered in 20 sessions lasting 50 minutes each over the course of 2-6 weeks. Up to two sessions may be scheduled per day with a one-hour interval in-between.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Subjects will still attend treatment sessions as outlined in the rTMS intervention. However, the device will not deliver any stimulation to the subject.
Study: NCT03845959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD0019 oral capsule
Description: TD0019 are green, hard capsule with size 0, containing yellow herbal powder with special smell of herbal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD0019 oral capsule
Description: TD0019 are green, hard capsule with size 0, containing yellow herbal powder with special smell of herbal.
Study: NCT00765726

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Moroctocog alfa(AF-CC)
Description: Dosing is at the discretion of the investigator during the study

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw for laboratory testing
Description: Hematology and Chemistry panels, Factor VIII inhibitor and recovery studies
Study: NCT03091920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-1973
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-1973
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study: NCT04084210

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juul Electronic cigarette
Description: The juul e-cigarette pods contain 0.7 ml nicotine by volume / 5% nicotine by weight.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juul Electronic cigarette
Description: The juul e-cigarette pods contain 0.7 ml nicotine by volume / 5% nicotine by weight.
Study: NCT03845959

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo
Study: NCT01776866

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary Angiography
Description: Coronary angiography include standard coronary angiography (SA) and dual-axis rotational coronary angiography (DARCA). Patient first undergo SA of either left or right coronary system followed by DARCA.
Study: NCT00665964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-3 polyethylene
Description: highly cross-linked polyethylene for knee arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N2Vac polethylene
Description: conventional polyethylene
Study: NCT02828332

Intervention type: OTHER
Group type: OTHER
Intervention: Vineland II (VABS -II)
Description: semi-structured interview with a psychologist; Measure 4 areas: Communication, skills of daily living, socialization and skills Motrices

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of life
Description: Evaluation of the quality of life and comorbidities
Study: NCT03054779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Canola Oil
Description: Regular canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High oleic acid canola oil
Description: High oleic acid canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Western diet oil combination
Description: A typical Western diet fat intake as a control treatment, comprised of 11% MUFA, 11% PUFA (9% omega-6 fatty acids and 2% omega-3 fatty acids), and 13% SFA, will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily
Study: NCT03448185

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fish oil
Description: Subjects randomized to omega-3 fatty acids will take 2 grams total of omega-3 per day for 1 year.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fish oil
Description: Subjects randomized to omega-3 fatty acids will take 2 grams total of omega-3 per day for 1 year.